Go Pro
NASDAQ:INAB

IN8bio Q2 2026 Earnings Report

IN8bio logo
$1.23 -0.01 (-0.81%)
Closing price 03:59 PM Eastern
Extended Trading
$1.20 -0.02 (-2.03%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 7, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

IN8bio Earnings Headlines

IN8bio (NASDAQ:INAB) Stock Price Down 5.3% - Should You Sell?
Elon says “don’t save money.” Is he right?
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days.tc pixel
In8bio (INAB) Stock Forecast & Price Target
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB) is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

View IN8bio Profile